Patents Assigned to Vanderbilt University
  • Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Patent number: 11345741
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 31, 2022
    Assignee: Vanderbilt University
    Inventors: James E. Crowe, Jr., Seth Zost, Robert Carnahan, Pavlo Gilchuk
  • Antagonists of the muscarinic acetylcholine receptor M4
    Patent number: 11325896
    Abstract: Disclosed herein are substituted 2-azaspiro[3.3]heptane compounds of formula (I?), which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: May 10, 2022
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Aaron M. Bender, Logan A. Baker
  • Quinazoline compounds as modulators of Ras signaling
    Patent number: 11318137
    Abstract: The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 3, 2022
    Assignee: Vanderbilt University
    Inventors: Alex G. Waterson, Jason R. Abbott, J. Phillip Kennedy, Stephen W. Fesik, Qi Sun, Jason Phan, Michael C. Burns, Pratiq Patel
  • System and method for providing biomechanically suitable running gait in powered lower limb devices
    Patent number: 11318028
    Abstract: Systems and methods for a running controller for a lower limb device including at least a powered knee joint are provided. The method includes collecting real-time sensor information for the lower limb device and configuring the lower limb device to a first state in a finite state model for an activity mode including the running mode. The method further includes, based on the sensor information, transitioning the lower limb device from a current state to a subsequent state in the finite state model for the detected mode when a pre-defined criteria for transitioning to the subsequent state is met, and repeating the transitioning until the activity mode changes. In the system and method, the finite state model includes at least one stance state and at least one swing state, where the at least one stance state includes at least one absorption state and at least one propulsion state.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: May 3, 2022
    Assignee: Vanderbilt University
    Inventors: Michael Goldfarb, Amanda Shultz, Brian Lawson
  • Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 11319304
    Abstract: Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: May 3, 2022
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Biosynthesis of everninomicin analogs in var
    Patent number: 11312986
    Abstract: Disclosed are methods of preparing everninomicin analogs by genetic alteration of Micromonospora carbonacea. Everninomicin analogs prepared by these methods and methods of using these analogs to treat infections are also disclose.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: April 26, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Brian O. Bachmann, Emilianne M. Limbrick, Kasia Derewacz
  • Polymeric vascular grafts which induce neovascularization with mild to minimal inflammation and promotion of fibrovascular tissue
    Patent number: 11305039
    Abstract: The present invention relates generally to shape memory polymer devices that are porous. The porosity of the device may generate advantageous neovascularization, decrease inflammation, and decrease fibrosis. The device may include a surface having a pore size of 500-750 microns and a pore spacing of 220-250 microns.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: April 19, 2022
    Assignees: Vanderbilt University, Venostent, Inc.
    Inventor: Timothy C. Boire
  • Linear polyester and semi-linear glycidol polymer systems: formulation and synthesis of novel monomers and macromolecular structures
    Patent number: 11305018
    Abstract: Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: April 19, 2022
    Assignee: Vanderbilt University
    Inventors: Eva M. Harth, Dain B. Beezer, GuangZhao Li, Benjamin R. Spears, David M. Stevens
  • Antagonists of the muscarinic acetylcholine receptor M4
    Patent number: 11299481
    Abstract: Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Grant
    Filed: October 20, 2018
    Date of Patent: April 12, 2022
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Julie L. Engers, Kayla J. Temple, Aaron M. Bender, Logan A. Baker
  • Human IgE antibodies binding to aspergillus allergens
    Patent number: 11299535
    Abstract: The present disclosure is directed to antibodies binding to Aspergillus allergens and methods for use thereof.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: April 12, 2022
    Assignee: VANDERBILT UNIVERSITY
    Inventor: Scott A. Smith
  • Robust interferometer and methods of using same
    Patent number: 11293863
    Abstract: Provided are improved optical detection systems and methods for using same, which systems and methods comprise single channel interferometric detection systems and methods for determining a characteristic property of samples. Such interferometric detection systems and methods employ a light beam that impinges two or more discrete zones along a channel, thereby avoiding variations that can result in increases in detection limits and/or measurement errors.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: April 5, 2022
    Assignee: Vanderbilt University
    Inventors: Darryl J. Bornhop, Michael Kammer
  • System and method for detecting and measuring the condition of intraluminal esophageal mucosa
    Patent number: 11291382
    Abstract: Disclosed are catheter systems and methods of using the catheter system to acquire mucosal impedance data of a patient. Also disclosed are methods of classifying or otherwise identifying esophageal conditions in a subject based on mucosal impedance data acquired using a catheter system. Unlike conventions systems that require subjective input from a physician to render a diagnosis, the systems and methods described herein can utilize the mucosal impedance measurements to generate a probability that the subject's esophagus corresponds to an esophageal condition or a set of esophageal conditions. In one embodiment, a classification model is used to generate the probability. The classification model may generate the probability based at least in part on a change in the mucosal impedance measurements between a distal location and a proximal location on the subject's esophagus.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 5, 2022
    Assignees: Diversatek Healthcare, Inc., Vanderbilt University
    Inventors: Michael F. Vaezi, Charles Lindsay, James M. Prinster
  • Application of anti-CD39L3 antibodies for use in disease diagnostics and imaging
    Patent number: 11287427
    Abstract: In spite of significant efforts to identify ?-cell-specific markers for ?-cell imaging and purification, progress has been limited. Herein is disclosed a novel biomarker of human pancreatic ?-cells, CD39L3 (also known as ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3)). Disclosed are compositions and methods for purifying and imaging ?-cell using anti-CD39L3 antibodies.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 29, 2022
    Assignees: VANDERBILT UNIVERSITY, THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Alvin C. Powers, Marcela Brissova, Chunhua Dai, Neil Phillips, Diane Saunders
  • Electrochemically actuated optical modulator
    Patent number: 11287642
    Abstract: A device according to one example of principles described herein may include a backplane, electrochemical actuator, and an optical resonator, wherein the electrochemical actuator is located between the backplane and optical resonator. Applied energy may be used to modify the volume of the electrochemical actuator material modifying the resonant/interferometric absorption, transmission, and reflection at visible and/or infrared frequencies.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: March 29, 2022
    Assignee: Vanderbilt University
    Inventors: Jason G. Valentine, Cary L. Pint, Zachary J. Coppens, Adam P. Cohn
  • Phage-mediated manipulation of
    Patent number: 11268100
    Abstract: The invention relates to systems, methods, and compositions for the genetic modification of Wolbachia.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 8, 2022
    Assignee: Vanderbilt University
    Inventors: Sarah R. Bordenstein, Seth R. Bordenstein
  • Methods and systems for ion mobility and mass analysis
    Patent number: 11264227
    Abstract: An ion manipulation device and systems and methods for controlling the ion manipulation device. The ion manipulation device includes a pair of counter-facing surfaces and a plurality of electrodes arranged in one or more linear array on each of the counter-facing surfaces. At least one RF power source is coupled to the electrodes and configured to apply an RF potential to the electrodes to create an electric field that inhibits charged particles from approaching the counter-facing surfaces. At least one DC power source is coupled to the electrodes and configured to apply a DC potential to affect the movement of ions between the counter-facing surfaces in a direction parallel to the counter-facing surfaces. The DC potential and the RF potential are applied to the electrodes simultaneously.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: March 1, 2022
    Assignee: Vanderbilt University
    Inventors: Katrina L. Leaptrot, Jody C. May, John A. Mclean
  • METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE
    Publication number: 20220054494
    Abstract: Methods of treating bladder or urethra dysfunction or disease in a subject and methods of increasing bladder smooth muscle contractility or increasing bladder wall volume in a subject are disclosed. In some examples, a purine nucleoside phosphorylase (PNPase) inhibitor or purine nucleoside substrate is administered, such as 8-aminoguanine or forodesine.
    Type: Application
    Filed: March 13, 2020
    Publication date: February 24, 2022
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Vanderbilt University, The Trustees of The University of Pennsylvania
    Inventors: Edwin Kerry Jackson, Lori Ann Birder, Amanda Sue Wolf-Johnston, Roger Dmochowski, Alan J. Wein
  • Multifunctional degradable nanoparticles with control over size and functionalities
    Patent number: 11254786
    Abstract: In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: February 22, 2022
    Assignee: Vanderbilt University
    Inventors: Eva M. Harth, David J. Calkins, Alice E. Van Der Ende
  • Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
    Patent number: 11247971
    Abstract: Provided is a compound of formula (I), in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: February 15, 2022
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE UAB RESEARCH FOUNDATION, VANDERBILT UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
  • Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 11242342
    Abstract: Isoquinoline amine compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: February 8, 2022
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew Felts